Article Text

Download PDFPDF
Original research
Occupational radiation and haematopoietic malignancy mortality in the retrospective cohort study of US radiologic technologists, 1983–2012
  1. Martha S Linet1,
  2. Mark P Little1,
  3. Cari M Kitahara1,
  4. Elizabeth K Cahoon1,
  5. Michele M Doody1,
  6. Steven L Simon1,
  7. Bruce H Alexander2,
  8. Dale L Preston3
  1. 1 National Cancer Institute Division of Cancer Epidemiology and Genetics, Bethesda, Maryland, USA
  2. 2 Division of Environmental Health Sciences, University of Minnesota, Minneapolis, Minnesota, USA
  3. 3 self-employed at Hirosoft International, Eureka, California, USA
  1. Correspondence to Dr Martha S Linet, Radiation Epidemiology Branch, National Cancer Institute Division of Cancer Epidemiology and Genetics, Bethesda, MD 20892-9778, USA; linetm{at}mail.nih.gov

Abstract

Objectives To evaluate cumulative occupational radiation dose response and haematopoietic malignancy mortality risks in the US radiologic technologist cohort.

Methods Among 110 297 radiologic technologists (83 655 women, 26 642 men) who completed a baseline questionnaire sometime during 1983–1998, a retrospective cohort study was undertaken to assess cumulative, low-to-moderate occupational radiation dose and haematopoietic malignancy mortality risks during 1983–2012. Cumulative bone marrow dose (mean 8.5 mGy, range 0–430 mGy) was estimated based on 921 134 badge monitoring measurements during 1960–1997, work histories and historical data; 35.4% of estimated doses were based on badge measurements. Poisson regression was used to estimate excess relative risk of haematopoietic cancers per 100 milligray (ERR/100 mGy) bone-marrow absorbed dose, adjusting for attained age, sex and birth year.

Results Deaths from baseline questionnaire completion through 2012 included 133 myeloid neoplasms, 381 lymphoid neoplasms and 155 leukaemias excluding chronic lymphocytic leukaemia (CLL). Based on a linear dose-response, no significant ERR/100 mGy occurred for acute myeloid leukaemia (ERR=0.0002, 95% CI <−0.02 to 0.24, p-trend>0.5, 85 cases) or leukaemia excluding CLL (ERR=0.05, 95% CI <−0.09 to 0.24, p-trend=0.21, 155 cases). No significant dose-response trends were observed overall for CLL (ERR<−0.023, 95% CI <−0.025 to 0.18, p-trend=0.45, 32 cases), non-Hodgkin lymphoma (ERR=0.03, 95% CI <−0.2 to 0.18, p-trend=0.4, 201 cases) or multiple myeloma (ERR=0.003, 95% CI −0.02 to 0.16, p-trend>0.5, 112 cases). Findings did not differ significantly by demographic factors, smoking or specific radiological procedures performed.

Conclusion After follow-up averaging 22 years, there was little evidence of a relationship between occupational radiation exposure and myeloid or lymphoid haematopoietic neoplasms.

  • epidemiology
  • occupational health practice
  • leukaemia
  • longitudinal studies
  • Ionising radiation

Statistics from Altmetric.com

Footnotes

  • Contributors Guarantees of integrity of entire study: all authors. Study conception/design: MSL, MPL, CMK, EKC, DLP. Data acquisition: MMD, BHA. Development of dosimetry system: SLS, MMD, DLP, ML. Data analysis: DLP. Data interpretation: all authors. Manuscript drafting: MSL, MPL, SLS, DLP. Manuscript revisions: all authors. Approval of final revised version: all authors.

  • Funding Intramural Research Program of the National Institutes of Health, National Cancer Institute, and the US Public Health Service of the Department of Health and Human Services, Bethesda, Maryland. No funding was received from industry.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available on reasonable request. Deidentified data are available from the principal investigator of the US radiologic technologists cohort study (Dr Cari Kitahara) on reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.